GlobeNewswire Inc.··Beam Therapeutics Inc.Beam Therapeutics' BEAM-302 Shows Durable Results in AATD, Paving Path to Accelerated FDA Approval
Beam Therapeutics presents Phase 1/2 data for BEAM-302 treating alpha-1 antitrypsin deficiency, showing durable efficacy and improved safety across 29 patients.
BEAMFDA approvalclinical trial